News
Scisparc
SPRC · NASDAQ
$1.33−$0.07 (−5.00%)TodayMarket closed ·
Prev close $1.40
Latest news
- NewsAkanksha Bakshi
Why Is SciSparc Stock Gaining Thursday?
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
- News
SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder
- Press releaseGlobe Newswire
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
- News
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
- Press releaseGlobe Newswire
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
- Press releaseGlobe Newswire
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
- NewsLekha Gupta
What's Going On With SciSparc Shares On Friday?
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults
- Press releaseGlobe Newswire
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
- NewsAvi Kapoor
Dow Jumps Around 200 Points; Best Buy Posts Upbeat Q1 Results
- NewsKaustubh Bagalkote
Why Is SciSparc Stock Skyrocketing On Thursday?
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
Market-Moving News for January 13th
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAkanksha Bakshi
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
- NewsAkanksha Bakshi
SciSparc And AutoMax Call Off Merger
- NewsAvi Kapoor
S&P 500 Falls 1%; Accenture Posts Upbeat Earnings
- NewsAvi Kapoor
Nasdaq Down Over 1%; US Initial Jobless Claims Fall
- News
Market-Moving News for September 25th
- NewsAvi Kapoor
Nasdaq Falls Over 100 Points; General Mills Earnings Top Views
- NewsAvi Kapoor
Dow Surges 250 Points; US Housing Starts Tumble In August
- NewsRishabh Mishra
Stock Market Today: S&P 500 Futures Dip, Dow Rises Ahead Of FOMC Decision On Interest Rates—General Mills, New Fortress, Cracker Barrel In Focus (UPDATED)
- News
Market-Moving News for September 17th
- NewsAvi Kapoor
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket
- NewsMohd Haider
SciSparc Stock Shoots Up Over 89% After Hours: What's Going On?
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.